Congestive Heart Failure (CHF) Drugs Market By Drug Class (ACE Inhibitors & ARBs, ARNI, Beta-Blockers, SGLT2 Inhibitors, Mineralocorticoid Receptor Antagonists, Diuretics, Vasodilators, sGC Stimulators, Cardiac Myosin Activators, Emerging Therapies); By Heart Failure Phenotype (HFrEF, HFmrEF, HFpEF, Advanced Heart Failure); By Treatment Phase (Initial GDMT Initiation, Chronic Management, Acute Decompensated Heart Failure, Post-Discharge Stabilization, High-Risk Worsening Heart Failure, Advanced Disease Management); By Care Setting (Hospitals, Heart Failure Clinics, Outpatient Cardiology Practices, Ambulatory Care Centers, Home-Based Care); By Geography, Segment Revenue Estimation & Forecast, 2026–2032

Congestive Heart Failure Drugs Market: GDMT Expansion, SGLT2 Class Broadening, Hospitalization Economics, and Decongestion Innovation Reshape Chronic HF Treatment

The Global Congestive Heart Failure Drugs Market was valued at USD 9.28 Billion in 2025 and is projected to reach USD 20.26 Billion by 2032, expanding at a CAGR of 11.80% during the forecast period.

 

The Congestive Heart Failure Drugs Market is commercially mature yet continues to expand through guideline-directed medical therapy, hospitalization-reduction outcomes, broader treatment of HFpEF, and evolving delivery approaches for fluid overload management. The market is no longer defined solely by legacy ACE inhibitors, beta-blockers, digoxin, and loop diuretics. Current value is increasingly concentrated in therapies that reduce cardiovascular mortality, lower heart failure hospitalization rates, improve post-discharge risk stratification, and address adherence and decongestion challenges in chronic disease management.

 

The disease pool is large enough to support multiple drug classes across chronic and acute-care settings. A 2025 Global Burden of Disease–based analysis estimated 55.5 million heart failure cases worldwide in 2021, more than doubling from 25.4 million in 1990. WHO also reported 19.8 million cardiovascular deaths in 2022, representing about 32% of all global deaths, making heart failure drugs part of a broader cardiovascular risk-management priority rather than a narrow specialty segment.

 

The United States represents a high-value market due to substantial disease prevalence, mortality burden, hospitalization rates, and treatment intensity. CDC data indicate that nearly 6.7 million adults aged 20 years or older are living with heart failure, while the condition was listed on 452,573 death certificates in 2023. HFSA projections estimate that U.S. prevalence will increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050, with a lifetime risk of approximately 24%, affecting roughly one in four individuals.

 

Treatment Economics Are Built Around Hospitalization Reduction

The value of heart failure therapies is increasingly linked to the prevention of disease progression and acute decompensation rather than symptomatic control alone. In the United States, the Heart Failure Society of America (HFSA) estimates that heart failure accounted for approximately USD 32 billion in direct medical costs and USD 14 billion in indirect costs in 2020, with projections indicating a substantial rise by 2050. This positions hospitalization reduction as both a clinical and commercial endpoint.

The burden of recurrent hospitalizations also underpins payer support for therapies with robust outcomes evidence. Heart failure remains a high-cost, recurrent condition concentrated in older patients with multiple comorbidities. In this context, therapies that reduce hospital admissions, emergency department visits, intravenous diuretic use, or early post-discharge deterioration are better positioned to sustain premium reimbursement than those demonstrating symptom improvement alone.

This outcomes focus is reflected in contemporary clinical trial design. Landmark studies such as PARADIGM-HF, DAPA-HF, EMPEROR, DELIVER, and VICTORIA have established cardiovascular mortality, heart failure hospitalization, urgent care visits, and worsening heart failure events as primary value-defining endpoints, reinforcing heart failure pharmacotherapy as an outcomes-driven therapeutic class in which reimbursement is closely aligned with event reduction.

 

Four-Pillar Guideline-Directed Medical Therapy as the Core Demand Driver in HFrEF

HFrEF represents the most well-defined commercial segment, supported by guideline-directed multi-class therapy. Contemporary management is anchored in ARNI or ACE inhibitor/ARB therapy, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. This has created a layered chronic treatment landscape in which clinical value is driven by combination therapy rather than reliance on a single agent.

Sacubitril/valsartan reshaped the RAAS segment by replacing enalapril as a higher-value disease-modifying option in eligible HFrEF patients. In PARADIGM-HF, cardiovascular death or HF hospitalization occurred in 21.8% of sacubitril/valsartan patients versus 26.5% with enalapril, with a hazard ratio of 0.80. This moved ARNI therapy into a premium position because it demonstrated superiority over an established ACE inhibitor benchmark.

SGLT2 inhibitors created the most important cross-specialty expansion in heart failure drugs. DAPA-HF showed dapagliflozin reduced worsening HF or cardiovascular death to 16.3% versus 21.2% with placebo, with a hazard ratio of 0.74. EMPEROR-Reduced showed empagliflozin lowered the combined risk of cardiovascular death or HF hospitalization by 25%. These results moved SGLT2 inhibitors from diabetes-centered products into foundational heart failure therapy.

MRAs remain a commercially durable class, supported by long-established but still clinically central mortality benefits. The RALES trial demonstrated that spironolactone reduced the risk of death by approximately 30% in patients with severe heart failure. Hydralazine in combination with isosorbide dinitrate continues to represent a targeted value segment, with the A-HeFT study showing a 43% reduction in mortality among Black patients with advanced heart failure, reinforcing a population-specific evidence base in which adoption is driven more by clinical implementation than by novel product innovation.

 

SGLT2 Inhibitors Are Expanding the Treatable HF Spectrum

The most significant recent market expansion is occurring beyond traditional HFrEF populations. The ESC 2023 focused update provided Class I, Level A recommendations for dapagliflozin and empagliflozin in HFmrEF and HFpEF to reduce heart failure hospitalization and cardiovascular mortality, while the NICE 2025 update further broadened chronic heart failure management through increased adoption of SGLT2 inhibitors and mineralocorticoid receptor antagonists, including consideration of combination therapy in HFpEF.

This shift is commercially important as HFpEF has historically had limited effective pharmacologic options. With rising prevalence in aging, obese, diabetic, hypertensive, and chronic kidney disease populations, HFpEF is emerging as a larger treatment segment. SGLT2 inhibitors are well positioned due to their ability to reduce hospitalization risk across ejection fraction categories and their clinical relevance across cardiology, nephrology, diabetes, and primary care settings.

Dapagliflozin’s DELIVER data strengthened this broader HF positioning. In DELIVER, cardiovascular death or worsening HF occurred in 16.4% of dapagliflozin patients versus 19.5% with placebo, with a hazard ratio of 0.82. This made SGLT2 inhibitors one of the few drug classes with credible evidence across reduced, mildly reduced, and preserved ejection fraction populations.

The market impact is visible in class positioning. AstraZeneca’s Farxiga and Boehringer Ingelheim/Eli Lilly’s Jardiance compete not only as diabetes brands but as cardiovascular and renal-risk platforms. Their heart failure value is driven by broad guideline inclusion, relatively simple dosing, and relevance across comorbidity-heavy populations.

 

Decongestion Remains a Large Symptom-Control and Access Market

Loop diuretics remain a fundamental component of heart failure management, as congestion is a primary driver of symptoms, emergency visits, hospitalizations, and post-discharge instability. In contrast to disease-modifying therapies such as ARNI or SGLT2 inhibitors, loop diuretics do not alter long-term disease progression but are essential for managing fluid overload that frequently precipitates acute decompensation.

A key recent development in this segment is Enbumyst. The FDA approved Enbumyst, a bumetanide nasal spray, on September 12, 2025, for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome in adults. It represents the first FDA-approved intranasal loop diuretic, introducing a novel route of administration in a class historically limited to oral and intravenous use.

The commercial relevance of this innovation is primarily practical. Intranasal bumetanide is positioned to address the gap between oral and intravenous diuretics, particularly in patients with fluid overload, variable oral absorption, worsening outpatient symptoms, or care pathways aimed at avoiding emergency escalation. In April 2026, Esperion completed its acquisition of Corstasis, incorporating Enbumyst into its cardiovascular portfolio as the first FDA-approved nasal spray loop diuretic.

Diuretic innovation is not intended to replace disease-modifying therapy; however, it can generate clinical and commercial value by facilitating outpatient decongestion, supporting heart failure clinic workflows, and reducing hospitalization risk associated with acute fluid overload.

 

Implementation Gap Is the Largest Untapped Market

The CHF therapeutics market is supported by a strong evidence base; however, underutilization of guideline-directed therapy remains a major clinical and commercial gap. The HFSA 2025 report indicates that fewer than one in four eligible patients with HFrEF receive quadruple guideline-directed medical therapy. A JAMA Cardiology analysis further estimates that full global implementation of quadruple GDMT could prevent approximately 1.19 million deaths annually.

Real-world treatment optimization remains limited by persistent dosing gaps. In the CHAMP-HF registry, only 1% of eligible outpatients with HFrEF were simultaneously receiving target doses of an ACE inhibitor/ARB/ARNI, beta-blocker, and mineralocorticoid receptor antagonist. Similarly, the ESC Heart Failure Long-Term Registry reported achievement of target dosing in 39.5% of patients for ACE inhibitors/ARBs, 13.2% for beta-blockers, and 23.5% for MRAs.

This reframes the market opportunity, as growth is driven not only by new pharmacologic approvals but also by improved implementation of existing therapies. Significant value potential lies in earlier treatment initiation, accelerated dose titration, discharge-based prescribing pathways, digital adherence solutions, structured heart failure clinics, and expanded access in resource-limited settings.

 

High-Risk and Worsening HF Remain Differentiated Treatment Windows

Vericiguat illustrates how targeted positioning can generate clinical and commercial value when the treatment window is clearly defined. Verquvo was approved by the FDA in 2021 to reduce cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and reduced ejection fraction below 45%, particularly following recent hospitalization or the need for outpatient intravenous diuretics. In the VICTORIA trial (n=5,050), the primary outcome occurred in 35.5% of patients receiving vericiguat versus 38.5% with placebo, corresponding to a hazard ratio of 0.90.

Rather than a broad first-line chronic heart failure therapy, vericiguat is positioned within the post-worsening heart failure setting, where patients remain at elevated risk despite background guideline-directed therapy. As a result, patient identification, NT-proBNP–based risk stratification, and structured post-discharge care transitions are key commercial drivers.

This framework reflects a broader trend in heart failure therapeutics, where market growth is increasingly driven by alignment with specific clinical care phases, including HFrEF initiation, HFpEF hospitalization prevention, post-discharge stabilization, outpatient congestion management, renal comorbidity overlap, and persistent residual risk in advanced disease.

 

Pipeline Direction Is More Selective After Mixed Innovation Outcomes

Heart failure drug development remains active; however, not all mechanisms meet current evidentiary and regulatory thresholds. The experience with omecamtiv mecarbil highlights this challenge. In February 2023, Cytokinetics received a U.S. FDA complete response letter indicating that an additional trial would be required to establish substantial evidence of efficacy, and the company did not plan to conduct a further study. This outcome recalibrated expectations for cardiac myosin activation in HFrEF following GALACTIC-HF, which demonstrated only modest reductions in clinical events without a clear survival or quality-of-life benefit.

Gene therapy represents a higher-risk but strategically important development pathway. AskBio and Bayer reported 12-month Phase 1 data for AB-1002, an investigational gene therapy for NYHA Class III non-ischemic HFrEF. Bayer indicated that no adverse events were considered related to AB-1002, with clinically meaningful improvements observed across multiple efficacy endpoints, while the Phase 2 GenePHIT trial is actively enrolling across Canada, Europe, the UK, and the United States.

Cell therapy remains an additional advanced heart failure focus area, although its commercial trajectory is less defined than small-molecule and SGLT2-based approaches. Mesoblast’s rexlemestrocel-L has shown interest in ischemic HFrEF with inflammatory phenotypes; however, prior Phase 3 results did not meet the primary endpoint of reducing hospitalizations, reinforcing the need for clearer endpoints, improved patient selection, and stronger regulatory alignment before regenerative therapies can become mainstream drivers of the chronic heart failure market.

 

Regional Market Direction

In North America, the most clinically relevant patient population is concentrated in relapsed or refractory hematologic malignancies where CD antigen expression can be confirmed and used to guide therapy selection. Non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute myeloid leukemia, and BPDCN constitute the core disease base supporting approved CD antigen-directed therapies.

Europe is a guideline-driven market where SGLT2 inhibitors and MRAs are gaining broader relevance across HF categories. More than 10 million people in the EU may be affected by heart failure, and HF has historically represented about 2% of healthcare expenditure, with one estimate placing EU HF-related costs near EUR 29 billion annually. This keeps drug access, hospitalization reduction, and post-discharge management central to European payer discussions.

Asia-Pacific offers the largest long-term patient-growth opportunity but also the widest access gap. Patients with heart failure in Asia are often younger than Western cohorts and present with more severe symptoms. India’s National Heart Failure Registry reported 10,850 patients with mean age of 59.9 years, 31% women, and ischemic heart disease in 71.9% of cases. The Trivandrum Heart Failure Registry reported 59% five-year mortality and only 25% GDMT use among HFrEF patients at discharge, showing how much market value is tied to treatment implementation rather than drug discovery alone.

 

Competitive Positioning

Novartis remains central through Entresto, which retains premium value in HFrEF because PARADIGM-HF established superiority over enalapril. AstraZeneca and Boehringer Ingelheim/Eli Lilly have gained broader heart failure relevance through SGLT2 inhibitors, with Farxiga and Jardiance expanding beyond diabetes into HFrEF, HFmrEF, HFpEF, CKD-linked risk, and hospitalization prevention.

Generic manufacturers remain important in ACE inhibitors, ARBs, beta-blockers, MRAs, loop diuretics, hydralazine, nitrates, and digoxin. Their role is access-heavy and price-constrained. Branded value survives where products demonstrate outcome superiority, cross-phenotype coverage, post-worsening benefit, or differentiated delivery.

Merck/Bayer’s Verquvo occupies a narrower high-risk HFrEF segment after recent decompensation. Esperion’s Enbumyst creates a delivery-led diuretic position in edema associated with CHF, hepatic disease, and renal disease. AskBio/Bayer’s AB-1002 gives the pipeline a gene-therapy signal, but this remains investigational and far from routine CHF prescribing.

 

Analyst Insight

The Congestive Heart Failure Drugs Market is entering an implementation-led growth phase. The science has already created several proven classes, but real-world use remains far below optimal levels. The strongest commercial upside is not only from new approvals; it is from better deployment of existing high-evidence therapies.

SGLT2 inhibitors are the most important class expansion story because they moved from diabetes into heart failure and now cover broader ejection-fraction categories. ARNIs remain the premium HFrEF RAAS-modifying segment. MRAs and beta-blockers remain foundational but under-dosed. Vericiguat targets high-risk post-worsening patients. Enbumyst adds delivery innovation to the decongestion segment.

The pipeline is more selective than the headline volume suggests. Omecamtiv mecarbil’s FDA rejection showed that modest event reduction is not enough when survival, quality of life, and safety questions remain. AB-1002 and regenerative therapies show long-range innovation, but near-term market growth will be driven more by guideline implementation, SGLT2 penetration, HFpEF expansion, post-discharge prescribing, and outpatient congestion management.

The most important market indicators are quadruple-GDMT uptake, SGLT2 adoption in HFpEF and HFmrEF, ARNI penetration, MRA dosing, post-discharge initiation rates, HF hospitalization trends, Enbumyst uptake in outpatient decongestion, and whether advanced therapies can generate randomized evidence strong enough to justify adoption.

 

Congestive Heart Failure (CHF) Drugs Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 9.28 Billion
Revenue Forecast in 2032	USD 20.26 Billion
Overall Growth Rate	CAGR of 11.80% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Heart Failure Phenotype, By Treatment Phase, By Care Setting, By Geography
By Drug Class	ACE Inhibitors & ARBs, ARNI, Beta-Blockers, SGLT2 Inhibitors, Mineralocorticoid Receptor Antagonists, Diuretics, Vasodilators, sGC Stimulators, Cardiac Myosin Activators, Emerging Therapies
By Heart Failure Phenotype	Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF), Heart Failure with Preserved Ejection Fraction (HFpEF), Advanced Heart Failure
By Treatment Phase	Initial GDMT Initiation, Chronic Management, Acute Decompensated Heart Failure, Post-Discharge Stabilization, High-Risk Worsening Heart Failure, Advanced Disease Management
By Care Setting	Hospitals, Heart Failure Clinics, Outpatient Cardiology Practices, Ambulatory Care Centers, Home-Based Care
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of guideline-directed medical therapy adoption across heart failure phenotypes, rising utilization of SGLT2 inhibitors beyond diabetes into HF management, increasing focus on hospitalization reduction and outpatient decongestion strategies
Customization Option	Available upon request